Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

U.S. President Joe Biden said on Wednesday (January 15) that Israel and Hamas have reached a ceasefire and hostage deal that ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

These innovative therapeutic modalities hold immense promise for addressing both genetic and acquired diseases, offering new avenues for improving patient outcomes and quality of life. According to ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Shareholders request Human Rights Due Diligence to determine whether pharma companies do everything they can to increase drug ...

The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

The growing emphasis on advanced liver fibrosis treatments highlights a paradigm shift in addressing chronic liver diseases, ...